Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study Unlike FH PV, FH-d PV are not associated with kidney ...
A phase 2 study showed a 93.3% objective response rate for lenvatinib and tislelizumab in FH-RCC patients, with a 20% complete response rate. FH-RCC is driven by FH gene mutations, leading to early ...
DANVILLE, Pa. - A study conducted by Geisinger Health System in collaboration with the Regeneron Genetics Center (RGC) has found that a life-threatening genetic disorder known as Familial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results